Baxter S.A. — China registrations and re-registration filing lines
5 certificates in the NMPA overseas-manufactured drug database (境外生产药品库), snapshot 2026-06-28. Earliest filing line: 2026-09-28.
| Approval number | Product | Certificate expires | Filing line (Art. 82) |
|---|---|---|---|
| 国药准字HJ20170154 | ClinOleic 长链脂肪乳注射液(OO) | 2027-03-28 | 2026-09-28 |
| 国药准字HJ20170155 | ClinOleic 长链脂肪乳注射液(OO) | 2027-03-28 | 2026-09-28 |
| 国药准字HJ20180019 | Oliclinomel 10%脂肪乳（OO）/5.5%氨基酸（15）/葡萄糖（20%）注射液 | 2028-03-19 | 2027-09-19 |
| 国药准字HJ20202000 | Oliclinomel 10%脂肪乳（OO）/5.5%氨基酸（15）/葡萄糖（20%）注射液 | 2028-03-19 | 2027-09-19 |
| 国药准字HJ20181203 | Cernevit 注射用多种维生素(12) | 2028-07-03 | 2028-01-03 |
Under the Provisions for Drug Registration (药品注册管理办法) Art. 82, an application to renew an overseas-manufactured drug registration is filed with the Center for Drug Evaluation no later than 6 months before the certificate expires; the filing line column is that arithmetic applied to the expiry cell. Art. 84(1): a certificate with no application by expiry is not re-registered and is cancelled at expiry. Every figure is taken from the public NMPA database as of 2026-06-28, or computed from it. Registration data changes; the NMPA portal governs. This page states no view on whether any of these products' Domestic Responsible Person (境内责任人) arrangements meet NMPA Announcement No. 137 — that cannot be determined from a public entry.